Realising the potential of biosimilars

Comment: Supporting a sustainable biosimilar solution

Comment: Use of biosimilar monoclonal antibodies in the clinic

Comment: Critical quality attributes of biosimilars

Comment: Immunogenicity of biosimilars

Simplifying molecular subtypes of metastatic gastric cancer

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

IMspire170: New combination treatment for advanced melanoma